Table 1.
Characteristics of study participants
| All participants (N = 90) | HIV-negative (N = 17) |
HIV-positive, overall (N = 73) |
HIVHigh Viral Load (N = 34) |
HIVLow Viral Load (N = 39) |
||||
|---|---|---|---|---|---|---|---|---|
| Two-dose (N = 17) | Two-dose (N = 42) | Three-dose (N = 31) | Two-dose (N = 20) | Three-dose (N = 14) | Two-dose (N = 22) | Three-dose (N = 17) | ||
| Female Sex, n (%) | 62 (69) | 12 (71) | 32 (76) | 18 (58) | 18 (90) | 7 (50) | 14 (64) | 11 (65) |
| Age (years) | ||||||||
| 19-35, n (%) | 38 (42) | 12 (71) | 22 (52) | 4 (13) | 12 (60) | 2 (14) | 10 (45) | 2 (12) |
| 36-49, n (%) | 32 (36) | 4 (24) | 16 (38) | 12 (39) | 5 (25) | 7 (50) | 11 (50) | 5 (29) |
| 50-64, n (%) | 20 (22) | 1 (6) | 4 (10) | 15 (48) | 3 (15) | 5 (36) | 1 (5) | 10 (59) |
| Median (IQR) | 39 (30–47) | 29 (23–37) | 35 (30–42) | 49 (41–53) | 34 (29–39) | 44 (40–52) | 39 (30–42) | 50 (42–53) |
| Range | 24–64 | 20–53 | 23–59 | 24–64 | 23–59 | 34–61 | 24–54 | 24–64 |
| Education status | ||||||||
| No formal education, n (%) | 11 (12) | 2 (71) | 5 (12) | 4 (13) | 2 (10) | 2 (14) | 3 (14) | 2 (12) |
| Primary school, n (%) | 47 (52) | 8 (47) | 26 (62) | 13 (42) | 12 (60) | 7 (50) | 14 (63) | 6 (35) |
| Secondary school, n (%) | 23 (26) | 6 (35) | 9 (21) | 8 (26) | 6 (30) | 2 (14) | 3 (14) | 6 (35) |
| Post-secondary, n (%) | 9 (10) | 1 (6) | 2 (5) | 6 (19) | 0 (0) | 3 (21) | 2 (9) | 3 (18) |
| Doses one and two, COVID-19 vaccination | ||||||||
| mRNA, n (%) | 64 (71) | 16 (94) | 38 (90) | 10 (32) | 17 (85) | 5 (36) | 21 (95) | 5 (29) |
| AstraZeneca, n (%) | 22 (25) | 0 (0) | 2 (5) | 20 (65) | 2 (10) | 9 (64) | 0 (0) | 11 (65) |
| Mixed mRNA/AstraZeneca, n (%) | 4 (4) | 1 (6) | 2 (5) | 1 (3) | 1 (5) | 0 (0) | 1 (5) | 1 (6) |
| Interval doses one and two, Median (IQR) (days) | 28 (22–75) | 23 (21–68) | 25 (22–36) | 75 (28–77) | 31 (23–67) | 74 (23–76) | 22 (21–27) | 76 (29–78) |
| Interval doses one and two, Range (days) | 16–280 | 18–87 | 16–243 | 21–280 | 22–243 | 21–93 | 16–71 | 21–280 |
| Interval doses two and three, COVID-19 vaccination (all third doses mRNA) | ||||||||
| Median (IQR) (days) | 189 (169–203) | NA | NA | 189 (169–204) | NA | 197 (146–204) | NA | 185 (183–203) |
| Range (days) | 12–244 | NA | NA | 12–244 | NA | 79–236 | NA | 12–244 |
| Time from last vaccine dose to blood draw | ||||||||
| Median (IQR) (days) | 53 (37–105) | 101 (54–105) | 102 (53–110) | 26 (16–38) | 75 (50–105) | 16 (14–26) | 106 (79–111) | 38 (25–38) |
| Range (days) | 11–222 | 21–112 | 17–222 | 11–67 | 17–222 | 13–34 | 37–125 | 11–67 |
| Duration of HIV infection (years) | ||||||||
| <10, n (%) | NA | NA | 25 (60) | 11 (35) | 12 (60) | 7 (50) | 13 (59) | 4 (24) |
| 10-19, n (%) | NA | NA | 15 (36) | 17 (55) | 6 (30) | 7 (50) | 9 (41) | 10 (59) |
| 20+, n (%) | NA | NA | 2 (5) | 3 (10) | 2 (10) | 0 (0) | 0 (0) | 3 (18) |
| Antiviral (ART) regimen | ||||||||
| First-line, n (%) | NA | NA | 39 (93) | 24 (77) | 17 (85) | 10 (71) | 22 (100) | 14 (82) |
| Second-line, n (%) | NA | NA | 3 (7) | 6 (19) | 3 (15) | 4 (29) | 0 (0) | 2 (12) |
| Third-line, n (%) | NA | NA | 0 (0) | 1 (3) | 0 (0) | 0 (0) | 0 (0) | 1 (6) |
| Duration of ART regimen (years) | ||||||||
| <10, n (%) | NA | NA | 27 (64) | 13 (42) | 13 (65) | 8 (57) | 14 (64) | 5 (29) |
| 10-19, n (%) | NA | NA | 14 (33) | 17 (55) | 6 (30) | 6 (43) | 8 (36) | 11 (65) |
| 20+, n (%) | NA | NA | 1 (2) | 1 (3) | 1 (5) | 0 (0) | 0 (0) | 1 (6) |
| Most recent CD4 T cell count among HIV-positive participants with available counts | ||||||||
| <200 copies/uL, n/N (%) | NA | NA | 7/40 (17) | 2/28 (7) | 6/18 (33) | 2/11 (18) | 1/22 (5) | 0/17 (0) |
| ≥200 copies/uL, n/N (%) | NA | NA | 33/40 (83) | 26/28 (93) | 12/18 (67) | 9/11 (82) | 21/22 (95) | 17/17 (100) |